Tvardi Therapeutics
TVRD
129 hedge funds and large institutions have $360M invested in Tvardi Therapeutics in 2018 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 37 increasing their positions, 32 reducing their positions, and 18 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
62% more capital invested
Capital invested by funds: $222M → $360M (+$138M)
44% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 18
16% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 32
11% more call options, than puts
Call options by funds: $21.7M | Put options by funds: $19.5M
7% more funds holding
Funds holding: 121 → 129 (+8)
3.65% more ownership
Funds ownership: 54.86% → 58.51% (+3.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carmignac Gestion
Paris,
France
|
+$8.53M |
| 2 |
First Manhattan
New York
|
+$5.29M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$4.93M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$3.5M |
| 5 |
Goldman Sachs
New York
|
+$2.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$12.7M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$2.27M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.6M |
| 4 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$990K |
| 5 |
California Public Employees Retirement System
Sacramento,
California
|
-$696K |
TVRD Hedge Fund Activity: Q2 2018 in Review
129 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q2 2018, worth a combined $360M — up 62% from $222M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new TVRD positions and 18 closed out — a net gain of 8 holders — while 37 added to existing stakes and 32 trimmed.
The largest buyer was Carmignac Gestion, opening a new position worth an estimated $8.53M. The largest seller was State Street, cutting an estimated $12.7M.
- 129 institutional investors held Tvardi Therapeutics (TVRD) as of Q2 2018, up from 121 in Q1 2018.
- Funds reported $360M of Tvardi Therapeutics stock for Q2 2018, up 62% quarter-over-quarter.
- 26 funds opened new Tvardi Therapeutics positions in Q2 2018 and 18 closed out, a net change of +8 holders.
- The largest Tvardi Therapeutics buyer in Q2 2018 was Carmignac Gestion, an estimated $8.53M added.
- The largest Tvardi Therapeutics seller in Q2 2018 was State Street, an estimated $12.7M sold.
Based on aggregated 13F filings for Q2 2018.